10x Genomics, Inc.

NasdaqGS:TXG 株式レポート

時価総額：US$2.7b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

10x Genomics マネジメント

マネジメント 基準チェック /44

10x Genomics'の CEO はSerge Saxonovで、 Jul2012年に任命され、 の在任期間は 12.08年です。 の年間総報酬は$ 8.29Mで、 6.6%給与と93.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の3.34%を直接所有しており、その価値は$ 90.59M 。経営陣と取締役会の平均在任期間はそれぞれ6.5年と5.3年です。

主要情報

Serge Saxonov

最高経営責任者

US$8.3m

報酬総額

CEO給与比率6.6%
CEO在任期間12.2yrs
CEOの所有権3.3%
経営陣の平均在職期間7.2yrs
取締役会の平均在任期間5.4yrs

経営陣の近況

Recent updates

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

10x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum

Oct 12

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

CEO報酬分析

10x Genomics の収益と比較して、Serge Saxonov の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$240m

Mar 31 2024n/an/a

-US$264m

Dec 31 2023US$8mUS$545k

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Sep 30 2019n/an/a

-US$100m

Jun 30 2019n/an/a

-US$105m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$1mUS$366k

-US$112m

報酬と市場: Sergeの 総報酬 ($USD 8.29M ) は、 US市場 ($USD 6.74M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Sergeの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Serge Saxonov (47 yo)

12.2yrs

在職期間

US$8,286,050

報酬

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Serge Saxonov
Co-Founder12.2yrsUS$8.29m3.34%
$ 89.8m
Benjamin Hindson
Co-Founder12.2yrsUS$4.43m2.69%
$ 72.2m
Eric Whitaker
Chief Legal Officer7.2yrsUS$3.88m0.12%
$ 3.2m
Michael Schnall-Levin
Founding Scientist & CTO2.7yrsデータなしデータなし
Cassie Corneau
Manager of Investor Relations and Strategic Financeno dataデータなしデータなし
Rebecca Port
Chief People Officer3.7yrsデータなしデータなし
Jens Durruthy
Associate Director of Product Managementno dataデータなしデータなし

7.2yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: TXGの経営陣は経験豊富で経験豊富です（平均在職期間は6.5年）。

取締役

名称ポジション在職期間報酬所有権
Serge Saxonov
Co-Founder12.2yrsUS$8.29m3.34%
$ 89.8m
Benjamin Hindson
Co-Founder12.2yrsUS$4.43m2.69%
$ 72.2m
Kimberly Popovits
Independent Director4.5yrsUS$338.71k0.0038%
$ 102.9k
John Stuelpnagel
Independent Chairman11.1yrsUS$403.59k2.03%
$ 54.4m
Shehnaaz Suliman
Independent Director5.1yrsUS$336.39k0.0038%
$ 102.9k
Alan Mateo
Directorless than a yearデータなしデータなし
Mathai Mammen
Independent Director7.1yrsUS$331.39k0.14%
$ 3.8m
Sridhar Kosaraju
Independent Director5.4yrsUS$346.39k0.029%
$ 790.5k
Sarah Polonius-Teichmann
Directorless than a yearデータなしデータなし

5.4yrs

平均在職期間

54.5yo

平均年齢

経験豊富なボード: TXGの 取締役会 は 経験豊富 であると考えられます ( 5.3年の平均在任期間)。